Murphy Capital Management Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ) by 0.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 88,818 shares of the company’s stock after selling 449 shares during the period. Johnson & Johnson comprises about 1.7% of Murphy Capital Management Inc.’s holdings, making the stock its 17th largest holding. Murphy Capital Management Inc.’s holdings in Johnson & Johnson were worth $11,491,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $25,000. Krane Funds Advisors LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $26,000. Crewe Advisors LLC lifted its stake in shares of Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after acquiring an additional 196 shares during the last quarter. Permanens Capital L.P. lifted its stake in shares of Johnson & Johnson by 50.0% in the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after acquiring an additional 100 shares during the last quarter. Finally, Thor Advisors LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $69,000. 72.01% of the stock is owned by institutional investors.
Shares of NYSE:JNJ opened at $131.33 on Friday. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The company has a market cap of $341.03 billion, a PE ratio of 14.85, a P/E/G ratio of 2.18 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The stock’s 50-day moving average is $129.92 and its 200 day moving average is $134.97.
JNJ has been the topic of a number of research analyst reports. Morgan Stanley restated an “equal weight” rating and set a $145.00 price target on shares of Johnson & Johnson in a report on Tuesday, August 27th. Barclays initiated coverage on Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Friday. Finally, Bank of America restated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $151.00.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What are high-yield dividend stocks?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.